LAUSR

Etizolam is a benzodiazepine (BZD). Etizolam is structurally different from BZDs as a thiophene replaces the benzene ring, and a triazole ring is fused to the diazepine ring, but etizolam's pharmacological profile is similar. Etizolam has been used to treat anxiety and panic disorders, to reduce depressive and somatization symptoms, and to induce muscle relaxation. Etizolam is used recreationally due to etizolam's reinforcing and sedative effects. Etizolam is available in tablet or powder form, or administered on blotter paper that can be placed on the tongue for oral absorption. Etizolam metabolises into two major metabolites α-hydroxyetizolam and 8-hydroxyetizolam and all three compounds can be detected in different biological specimens using various common analytical techniques such as immunoassay, chromatography and mass spectrometry. Etizolam is a controlled drug in many countries around the globe but is approved for medical use in some countries, such as Japan, South Korea and Italy. This work is a collation and review of available literature on etizolam to help improve the fundamental understanding of its toxicology, outline best analytical practice, and aid interpretation of toxicology results.